A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Abroad (travel likely)RecruitingPHASE3

Conditions

Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai East Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Caicun Zhou)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Lund, Sweden

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

NSCLC (Advanced Non-small Cell Lung Cancer) · Brain Metastasases

Abroad (travel likely)Recruiting

Shanghai, China

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2, PHASE3

Birmingham, United States · Anchorage, United States

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE2

Fountain Valley, United States · Santa Rosa, United States